These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 28062615)
21. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Chen HH; Lainchbury JG; Matsuda Y; Harty GJ; Burnett JC Hypertension; 2001 Aug; 38(2):187-91. PubMed ID: 11509474 [TBL] [Abstract][Full Text] [Related]
22. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Volpe M; Carnovali M; Mastromarino V Clin Sci (Lond); 2016 Jan; 130(2):57-77. PubMed ID: 26637405 [TBL] [Abstract][Full Text] [Related]
23. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. Margulies KB; Perrella MA; McKinley LJ; Burnett JC J Clin Invest; 1991 Nov; 88(5):1636-42. PubMed ID: 1658047 [TBL] [Abstract][Full Text] [Related]
24. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. Schirger JA; Grantham JA; Kullo IJ; Jougasaki M; Wennberg PW; Chen HH; Lisy O; Miller V; Simari RD; Burnett JC J Am Coll Cardiol; 2000 Mar; 35(3):796-801. PubMed ID: 10716485 [TBL] [Abstract][Full Text] [Related]
30. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Wegner M; Hirth-Dietrich C; Stasch JP Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244 [TBL] [Abstract][Full Text] [Related]
31. Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage. Kato J Peptides; 2020 Oct; 132():170352. PubMed ID: 32610060 [TBL] [Abstract][Full Text] [Related]
32. Vasopeptidase inhibition: a new concept in blood pressure management. Burnett JC J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842 [TBL] [Abstract][Full Text] [Related]
33. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Pankow K; Wang Y; Gembardt F; Krause E; Sun X; Krause G; Schultheiss HP; Siems WE; Walther T Circ Res; 2007 Oct; 101(9):875-82. PubMed ID: 17823376 [TBL] [Abstract][Full Text] [Related]
34. Natriuretic peptides and cardio-renal disease. Volpe M Int J Cardiol; 2014 Oct; 176(3):630-9. PubMed ID: 25213572 [TBL] [Abstract][Full Text] [Related]
35. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction. Quaschning T; Galle J; Wanner C Kidney Int Suppl; 2003 May; (84):S54-7. PubMed ID: 12694309 [TBL] [Abstract][Full Text] [Related]
36. Interpretation of B-type natriuretic peptides in the era of angiotensin receptor-neprilysin inhibitors. Bettencourt P; Fonseca C; Franco F; Andrade A; Brito D Rev Port Cardiol; 2017 Dec; 36(12):881-884. PubMed ID: 29225105 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Ferro CJ; Spratt JC; Haynes WG; Webb DJ Circulation; 1998 Jun; 97(23):2323-30. PubMed ID: 9639376 [TBL] [Abstract][Full Text] [Related]
38. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Mangiafico S; Costello-Boerrigter LC; Andersen IA; Cataliotti A; Burnett JC Eur Heart J; 2013 Mar; 34(12):886-893c. PubMed ID: 22942338 [TBL] [Abstract][Full Text] [Related]